Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelics Industry News Stories for the Week of July 27th – August 2nd, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
Ego-Death Has Many Definitions and Means Different Things to Different People Once They Have a Psilocybin-Induced Experience
One of the outcomes that is still not fully understood in using Psilocybin in psychotherapy is the “Ego-Death” or “Ego-Dissolution” experience of those who take it during a controlled therapy session. It is this experience that has profoundly changed lives.
The State of the Cannabis Industry 2020 Reviews Data Points Around B2B Ordering, Consumer Preferences, Purchasing Habits and Human Resources Management
After the largest spike, shown in 4/20, sales stabilized as states deemed dispensaries essential. This stabilization, however, settled at much higher rates than the previous year, from late April through May and the first part of June.
Should Drugs Be Considered as Treatments for All Types of Newly Outlined “Nonmedical” Human Health and Wellness Issues, Including Mental Health?
“What needs to happen is more of a dialogue globally on why these Psychedelics can be medicines and why they can be beneficial to society, based on science and data,” JR Rahn, founder and CEO of MindMed (OTCQB:MMEDF).
Marijuana Businesses Could Pump up to $130 Billion Annually into the U.S. Economy by 2024, a Staggering Figure That Highlights the True Reach of the Nation’s Cannabis Industry
Estimates published in the newly released Marijuana Business Factbook show the total economic impact of legal cannabis sales increasing from $38 billion-$46 billion in 2019 to $106 billion-$130 billion by 2024 – a 181% increase.
Most Study Participants Said They Would Want to Take Psilocybin Again
Psilocybin, the active substance in Magic Mushrooms, has been consumed for centuries, although it does not seem to exhibit the same addictive traits as other psychoactive substances. According to a new study, users seek psilocybin for its ability to produce unique changes in the human conscious experience, giving rise to “meaning, insight, the experience of beauty and mystical-type effects.”
The House of Representatives on Thursday Voted in Favor of an Amendment to Protect All State, Territory and Tribal Marijuana Programs From Federal Interference
The measure, which would prevent the Department of Justice from using its funds to impede the implementation of cannabis legalization laws, passed in a 254-163 vote on the floor. Earlier in the day, it had been approved in an initial voice vote.
A New Review From Neuroethicist Eddie Jacobs is Suggesting Psilocybin May Have Great Potential as a Treatment for Obsessive-Compulsive Disorder (OCD)
Jacobs, from King’s College London and the University of Oxford, says it is surprising how little focus has been on the therapeutic potential of Psilocybin in treating OCD, and he points to a number of new clinical trials that are finally exploring this promising treatment.
Legal Sales Have Boomed Since March, Though it’s Hard to Say How Many Customers Previously Bought From Illegal Dealers
The legal marijuana industry has spent years battling illegal sellers who have eaten away at its market share and undercut its prices. But the coronavirus has proven to be a boon for legal pot shops, as customers fear the risks associated with inhaling questionable products and are nervous about letting sellers into their homes.
The Latest News on IP 34 and IP 44, Oregon’s Drug Reform Initiatives
A Democratic Senator Filed a New Bill to Federally Legalize Marijuana on Thursday, Creating Yet Another Potential Avenue Through Which Congress Could Enact the Policy Change
This piece of legislation, sponsored by Sen. Tina Smith (D-MN), would remove cannabis from the Controlled Substances Act and direct several federal agencies to develop regulations for the plant.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.